Trinity Biotech TRIB
NASDAQ TRIB
$7.76 -0.26 (-3.24%)
As of: Oct 21, 2026 · 3:31 PM EDT

Trinity Biotech (TRIB) Deferred Taxes (2023 - 2024)

Updated

Trinity Biotech (TRIB) posted Deferred Taxes of -$1.24 million for the quarter ended Dec 31, 2024, compared with -$611,000 a year earlier.

Analysis

Trinity Biotech (TRIB) Deferred Taxes (2023 - 2024) Analysis & Trends

For the trailing twelve months through Dec 31, 2024, Deferred Taxes at Trinity Biotech was -$1.28 million; for the year ended Dec 31, 2023, it came in at -$1.17 million.

  • In prior years, Trinity Biotech's Deferred Taxes was -$303,000 in the year ended Dec 31, 2022, -$1.22 million in the year ended Dec 31, 2021, -$36,000 in the year ended Dec 31, 2020 and -$697,000 in the year ended Dec 31, 2019.
  • The figure for the quarter ended Dec 31, 2024 stands as the lowest quarterly Deferred Taxes in data going back to the quarter ended Jun 30, 2021.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Deferred Taxes (Qtr)
1 Thermo Fisher Scientific 257.99 Bn 237.02 Bn 4.88 Bn -208.00 Mn
2 Abbott Laboratories 175.01 Bn 145.44 Bn 7.27 Bn -
3 Danaher 164.93 Bn 148.74 Bn 3.61 Bn -
4 Intuitive Surgical 151.84 Bn 131.26 Bn 1.96 Bn 31.00 Mn
5 Medtronic 119.05 Bn 84.30 Bn 6.34 Bn 127.00 Mn
6 Stryker 113.89 Bn 100.00 Bn 4.50 Bn 107.00 Mn
7 Boston Scientific 65.37 Bn 60.13 Bn 3.85 Bn 17.00 Mn
8 Becton Dickinson 53.36 Bn 50.51 Bn 2.32 Bn -74.00 Mn
9 Edwards Lifesciences 50.83 Bn 34.83 Bn 1.35 Bn 181.30 Mn
10 Trinity Biotech 5.05 Mn -17.64 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2024 16,000.00
Sep 30, 2023 403,000.00
API Access

Trinity Biotech Deferred Taxes API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=deferred-taxes&ticker=TRIB&period=max&api_key=YOUR_API_KEY